We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · January 03, 2021

Long-Acting Cabotegravir and Rilpivirine in HIV-1

The Lancet


Additional Info

The Lancet
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With HIV-1 Infection (ATLAS-2M), 48-Week Results: A Randomised, Multicentre, Open-Label, Phase 3b, Non-Inferiority Study
Lancet 2021 Dec 19;396(10267)1994-2005, ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, F Bredeek, M García Deltoro, S Swindells, JF Andrade-Villanueva, A Wong, MA Khuong-Josses, R Van Solingen-Ristea, V van Eygen, H Crauwels, S Ford, C Talarico, P Benn, Y Wang, KJ Hudson, V Chounta, A Cutrell, P Patel, M Shaefer, DA Margolis, KY Smith, S Vanveggel, W Spreen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading